ArticleJournal of clinical and translational science2026
Untargeted metabolomics of cervicovaginal fluid in patients with ovarian cancer.
Article in Journal of clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cervicovaginal fluid (CVF) represents a promising biospecimen for ovarian cancer biomarker discovery, but metabolomics typically requires specialized collection methods. We assessed the feasibility of applying untargeted metabolomics to self-collected CVF from 10 ovarian cancer patients in the ORCHiD (Ovarian Cancer Epidemiology, Healthcare Access and Disparities) study using ultrahigh performance liquid chromatography-tandem mass spectroscopy. We detected 1107 compounds mapping to 1002 unique metabolite identifiers across 9 super chemical classes, with detection rates of 62-99%. One-third of detected metabolites overlapped with published studies, while two-thirds were novel. Sample-level detection profiles were broadly consistent. Untargeted metabolomics on self-collected CVF is technically feasible and enables metabolite discovery for population-based cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.